Lynx1 Capital Management LP

10% owner

Lynx1 Capital Management LP (10% owner) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Passage Bio, Inc. (PASG). Across 5 priced purchase filings, the average 21-session return was +14.0% from execution and +10.1% from disclosure (delay-adjusted; derived). The largest single filing was $9.8M of CGEM (1,459,641 sh across 3 lots, as filed), executed Oct 8 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+14.0%

avg across 5 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+10.1%

same 5 filings, from disclosure

Filings, ttm

5 buys · 0 sells · 1 late

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$16.8M

shares × price, as filed

Last traded

Jun 25

Filed Jun 29

Median ADV $20.1M across their filed names

Impact on $10,000 · 12M

$17,549 (+75.5%)

S&P 500 $11,725 (+17.2%) · 58.2 pts ahead

Lynx1 Capital Management LP S&P 500

Compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $21.2M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 4 filings Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names

PASG

Passage Bio, Inc. PASG · 5 buys · 0 sells 5 filings CGEM

Cullinan Therapeutics, Inc. CGEM · 3 buys · 0 sells 3 filings NEUP NEUP NEUP · 1 buy · 0 sells 1 filing TCRX TCRX TCRX · 1 buy · 0 sells 1 filing

Recent filings

PASGPURCHASE Passage Bio, Inc. View filing → $243K
373,645 sh × $0.65
Exec Dec 27 2024
Filed Dec 31 2024 · 5:30 PM ET PASGPURCHASE Passage Bio, Inc. View filing → $264K
427,053 sh across 2 lots
Exec Nov 25 2024
Filed Nov 27 2024 · 5:30 PM ET